Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

/p>

GAAP net sales for the 2009 second quarter totaled $4.6 billion, down 6 percent as compared to the second quarter of 2008, reflecting operational growth of 4 percent and an unfavorable impact from foreign exchange of 10 percent during the quarter.

Net sales of the cholesterol joint venture with Merck & Co., Inc., which include VYTORIN and ZETIA, totaled $1.0 billion in the 2009 second quarter. Schering-Plough does not record sales of its cholesterol joint venture with Merck as the venture is accounted for under the equity method. Including an adjustment of an assumed 50 percent of the global cholesterol joint venture net sales, Schering-Plough's adjusted net sales for the 2009 second quarter would have been $5.2 billion.

"Our diverse product strength - from REMICADE to TEMODAR to NUVARING to MIRALAX - and our rich geographic diversity helped drive our operational growth. In fact, we grew sales in most regions around the world on an operational basis. Achieving operational growth on such a broad front in the midst of a severe global recession is no small feat," said Hassan.

Regarding the company's R&D strength, the company highlighted its strong R&D engine and steady product flow as a special asset at a time when R&D innovation in the industry is so critical. The company noted that the "Five Stars" in its product pipeline, highlighted at its November 2008 R&D Update meeting, continued to advance: thrombin receptor antagonist (TRA), in Phase III for atherothrombosis; SIMPONI (golimumab), a subcutaneous treatment for certain inflammatory diseases; SAPHRIS (asenapine), for the acute treatment of schizophrenia and bipolar disorder; boceprevir, a protease inhibitor in Phase III for hepatitis C; and BRIDION (sugammadex), an innovative agent for use in anesthesiology.

The company's R&D engine has produced a number of recent regulatory and pipeline
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Biosciences Corporation announced today the enrollment and dosing at ... of the first patient in the ACE ( ... Phase 2 pivotal trial in patients with relapsed or ... novel, orally available, potent and highly selective small molecule ... (FLT3) inhibitor. The ACE study is designed to ...
(Date:12/11/2009)... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ... appointment of Dr. Alan Warrander to the role ... Development. ,, "Dr. Warrander will be responsible for ... REOLYSIN(R)," said Dr. Brad Thompson, President and CEO ... design of a Phase 3 trial examining REOLYSIN ...
(Date:12/10/2009)... 10 Endologix, Inc. (Nasdaq: ELGX ... disorders, announced today that Dan Lemaitre, former President ... Board of Directors effective December 11, 2009. ... non-independent directors. ,, Franklin D. Brown, Chairman of ... Dan Lemaitre to the Endologix Board of Directors. ...
(Date:12/10/2009)... MISSISSAUGA, ON, Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences ... a life sciences product development company that identifies ... products at various stages of development, today provided ... result in the merger of Cytopia Ltd. into ... 5, 2009. The board of directors of Cytopia ...
Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Endologix Appoints Dan Lemaitre to its Board of Directors 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4
... /PRNewswire-FirstCall/,-- Cephalon, Inc., (Nasdaq: CEPH ) announced ... Human Use (CHMP) of the European,Medicines Agency has ... buccal tablet pain medication. In March 2007, Cephalon,submitted ... treatment of,breakthrough pain in adult cancer patients who ...
... quality, practice management and reimbursement content ... available through web-based delivery platform, DALLAS-FORT WORTH, Texas, ... and services to help accelerate,advancements in the treatment of ... delivery of healthcare,information, have joined forces to bring Oncology ...
... Jan. 24 Aton Pharma, Inc., ... that it has,launched an expanded, comprehensive ... and patient education resources, for the,dry ... Lacrisert is a unique preservative-free, once-daily*, ...
Other Biology Technology:Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 3Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 4Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 2Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 3Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 2Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 3
(Date:12/11/2009)... Malus orientalis species of wild apples that could ... the Middle East and Central Asia. A new study ... varieties from Georgia and Armenia with previously collected ... population and establishes a core collection that will make ... and research communities. , To identify and record the ...
(Date:12/11/2009)... Western Reserve University has granted an 18-month, exclusive ... portfolio of insulin analogs. The company must reach ... to obtain an exclusive license on therapies designed ... Diabetes is developing treatments that it hopes will ... rapidly growing insulin market. Insulin is a therapeutic ...
(Date:12/11/2009)... 4th edition of Springer,s classic reference and textbook Vogel ... A. McKusick Leadership Award. The prize, which recognizes Professor ... was presented to him at the 59th Annual Meeting ... October 2009 in Honolulu, Hawaii. , Motulsky is Professor ... of Washington in Seattle. One of the founding giants ...
Breaking Biology News(10 mins):Understanding apples' ancestors 2Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2New Hospitals Therapeutic Design Supports Healing Green Practices 60015 1New Hospitals Therapeutic Design Supports Healing Green Practices 60015 2New Hospitals Therapeutic Design Supports Healing Green Practices 60015 3New Hospitals Therapeutic Design Supports Healing Green Practices 60015 4Holiday Toy Safety 3A Tips to Protect Young Eyes 60011 1Holiday Toy Safety 3A Tips to Protect Young Eyes 60011 2Holiday Toy Safety 3A Tips to Protect Young Eyes 60011 3Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 1Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 2Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 3Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 4
... ways creates a sustained, partial correction to bleeding problems in ... with the development of gene therapy treatment for Hemophilia A, ... can cause serious internal bleeding in people. , Researchers at ... College of Medicine improved a vector -- a vehicle that ...
... concentration in the earth's atmosphere shows that a sharp rise ... evolutionary boost they needed to dominate the planet, according to ... author of a paper published Sept. 30 in the journal ... abundance of carbon 13, a byproduct of photosynthesis, in ...
... critical to the migratory success of many bird species. ... of migratory birds to orient to magnetic signals, researchers ... may be more complex than previously thought and that ... more than one mechanism. The work is reported in ...
Other Biology News:Gene therapy advance treats hemophilia in mouse models 2Gene therapy advance treats hemophilia in mouse models 3Oxygen increase caused mammals to triumph, researchers say 2Overbearing colored light may reveal a second mechanism by which birds interpret magnetic signals 2
... DNA Engine Dyad thermal cycler is ... (PCR). The chassis accommodates a variety ... assemblies), which hold different types and ... graphical programming with point-and-click navigation. Peltier ...
... IHC Select Immunophosphatase Secondary Detection System is ... Select Prediluted Primary Antibody reagents, which contain ... identification of antigens by light microscopy in ... Detection System may also be used with ...
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
Biology Products: